SEC Comment Letter for Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524) (JAZZ) — Dec 11, 2018
Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524)
Date: Dec. 11, 2018 · CIK: 0001232524 · Accession: 0000000000-18-037773
AI Filing Summary & Sentiment
File numbers found in text: 001-33500
Letter
December 11, 2018 Bruce Cozadd Chairman and Chief Executive Officer and Director Jazz Pharmaceuticals plc Fifth Floor, Waterloo Exchange Waterloo Road, Dublin 4, Ireland Re:Jazz Pharmaceuticals plc Form 10-K for the Fiscal Year Ended December 31, 2017 Filed February 27, 2018 File No. 001-33500 Dear Mr. Cozadd: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
December 11, 2018
Bruce Cozadd
Chairman and Chief Executive Officer and Director
Jazz Pharmaceuticals plc
Fifth Floor, Waterloo Exchange
Waterloo Road, Dublin 4, Ireland
Re:Jazz Pharmaceuticals plc
Form 10-K for the Fiscal Year Ended December 31, 2017
Filed February 27, 2018
File No. 001-33500
Dear Mr. Cozadd:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance